<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40285">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02028923</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2013-01</org_study_id>
    <nct_id>NCT02028923</nct_id>
  </id_info>
  <brief_title>Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds</brief_title>
  <acronym>EMGEL</acronym>
  <official_title>Phase III Study Evaluating the Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Rene Huguenin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Louis Mourier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III study aims to show that topical morphine low doses treats localized pain in
      chronic wounds, intense and rebellious to systemic analgesics included or not opioids.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg for the last 72 hours of the study</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg (either up to 3 tablets 10 mg per day) for the last 72 hours of the study (day 8 to day 11) and for which the basic treatment is unchanged throughout the duration of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in average daily pain intensity score on a numerical rating scale self assessment, measured on an 11-point between day 1 and day 11</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction in average daily pain intensity score on a numerical rating scale (where 0=no pain and 10=worst possible pain) self assessment, measured on an 11-point between day 1 and day 11. Therefore patients evaluate each morning local pain of the previous 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the percentage of local pain relief for 24 hours on a rating scale from 0 to 100%</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess and characterize the evolution of local pain on a global impression scale change : Pain related Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC)</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess patient satisfaction with treatment of local pain (score 0-4)</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact score of local pain on sleep (self-report scale of 0 to 100%)</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>0% no impact of pain on sleep 100% maximum impact of pain on sleep, inability to sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the time (in hours) before using oral immediate-release morphine after application of local treatment</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of cumulative dose of oral immediate-release morphine (in milligrams) of the 11 days of treatment for relieving painful access of local origin</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate systemic and local side effects of analgesic treatment (incidence, severity and location)</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the systemic absorption of topical morphine blood test after the first application</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Local Pain</condition>
  <condition>Chronic Wounds</condition>
  <arm_group>
    <arm_group_label>Morphine gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>morphine 30 mg, quantity of gel per application: 15mg (15ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neutral gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>water for injection, quantity of gel per application: 15mg (15ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine gel</intervention_name>
    <description>Topical</description>
    <arm_group_label>Morphine gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neutral gel</intervention_name>
    <description>Topical</description>
    <arm_group_label>Neutral gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged over 18 years

          -  Painful chronic wounds (bedsores, wound tumor, arterial ulcers, venous or mixed
             diabetic ulcer if systolic pressure index &gt;0.8, necrotic angiodermatitis not
             graftable), a bottom surface 300 cm² and does not require more than 15 ml of gel by
             application. When patient has multiple painful chronic wounds, the wound having only
             the highest pain intensity is considered for evaluation.

          -  Ineffective systemic analgesic with or without opioid analgesic established and
             maintained at the same dose for 3 days before inclusion. If treatment includes
             morphine, the daily dose should not exceed 60 mg of morphine equivalent and this
             treatment must be a treatment exclusive background.

          -  Patient requiring an analgesic equilibration for intense and rebellious local pain,
             with a daily average score greater than or equal to 5, on a graduated numerical scale
             of 0 to 10. The score is defined at the inclusion and corresponds to the pain
             intensity felt locally by the patient under treatment systemic analgesic with or
             without co-analgesics.

          -  If analgesics to treat systemic pain is ongoing, it must have been introduced for
             more than 3 days (according to criteria 3)

          -  If antidepressant treatment is in progress, it must have been established for over a
             month for a tricyclic and for more than 15 days for other classes of antidepressants.

          -  If an anti-epileptic treatment analgesic is in progress, it must have been
             established for over 15 days.

          -  Signing of the informed consent form.

          -  Patient able to respond the self-assessment questionnaires (sufficient understanding
             assessments, proficiency in French).

          -  Patient affiliated to an health insurance plan

        Exclusion Criteria:

          -  Allergy to morphine or carboxymethylcellulose or history of intolerance to morphine

          -  Analgesic at baseline including systemic morphine to greater than 60 mg equivalent
             dose of morphine treatment

          -  Fistulated wound

          -  Heavily exuding wound

          -  Wound bleeding (spontaneous bleeding)

          -  Ongoing radiotherapy on chronic wound

          -  Creatinine &gt; 110 µmol/L, Total bilirubin &gt; 20 µmol/L

          -  Not communicating patient

          -  Unable to comply with requirement of the protocol (11 days)

          -  Patient pregnant or of childbearing age without contraceptive therapy or lactating

          -  Person deprived of liberty or under guardianship

          -  Only for pharmacokinetic analysis: analgesics at baseline including morphine or
             hydromorphone or oxycodone or codeine. Fentanyl is allowed
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Virginie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie - Hôpital René Huguenin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Audrey Hurgon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Curie - Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia TRESCA, Leader</last_name>
    <phone>33156245630</phone>
    <email>patricia.tresca@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle TURBIEZ, Manager</last_name>
    <phone>33147111659</phone>
    <email>isabelle.turbiez@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <state>Ile de France</state>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Charru, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Charru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irène KRIEGEL, MD</last_name>
      <email>irene.kriegel@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Irène Kriegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Bichat</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Faucher, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nathalie Faucher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean-Jaurès</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Revnic, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julia Revnic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <state>Ile de France</state>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginie Laurent, MD</last_name>
      <phone>33147111515</phone>
      <email>virginie.laurent@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Virginie Laurent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>January 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>topical morphine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
